氨磺必利与奥氮平治疗首发精神分裂症对照研究

A control study of amisulpride vs.olanzapine in the treatment of first-episode schizophrenia

目的 探讨氨磺必利与奥氮平治疗首发精神分裂症的临床疗效和安全性.方法 将70例精神分裂症患者随机分为两组,分别口服氨磺必利及奥氮平治疗.观察8周.采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应.结果 治疗8周末,氨磺必利组显效率68.6％、有效率88.6％,奥氮平组分别为65.7％、85.7％,两组比较差异无显著性（P＞0.05）.两组不良反应均较轻微,经对症处理后均可减轻或缓解.结论 氨磺必利治疗首发精神分裂症疗效显著且与奥氮平相当,安全性高,依从性好.

Objective To explore the efficacy and safety of amisulpride vs.olanzapine in the treatment of first-episode schizophrenia. Methods Seventy patients with schizophrenia were randomly divided into two groups taking orally amisulpride and olanzapine respectively for 8 weeks. Efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS）. Results At the end of the 8^th week obvious effective and effective rate were respectively 68.6% and 88.6% in amisulpride and 65.7% and 85.7% in olanzapine group, which showed no significant intergroup differences （P〉0. 05）. Adverse reactions of both groups were mild and lightened or relieved after symptomatic treatment. Conclusion Amisulpride has an evident effect equivalent to olanzapine, higher safety and better compliance in the treatment of first-episode schizophrenia.